Firebrick Pharma Appoints Nilesh Wadhwa To Lead Global Business Development And Licensing

Firebrick Pharma Limited has announced the appointment of Nilesh Wadhwa as its new Head of Business Development and Licensing, following an extensive international search. He will officially take on the role from April 1, 2026, and will be based in Australia after a short transition period. Wadhwa brings nearly three decades of experience in pharmaceutical partnering, international strategy, and market expansion. 

Incoming Head of Business Development and Licensing, Nilesh Wadhwa, commented: "I am thrilled to join Firebrick Pharma at such a crucial stage in its journey. The Company’s innovative portfolio and clear vision for international expansion present a unique opportunity, and I look forward to working with Peter and the team to drive commercial success and long-term value for our shareholders."

Over the course of his career, he has worked with several leading global healthcare companies, contributing to major business development initiatives and strategic growth across multiple regions. He previously held leadership roles at Johnson & Johnson, where he led external innovation partnerships and executed key transactions across Asia. He also managed regional business development and strategy for Sanofi and Takeda Pharmaceuticals across Asia-Pacific, further strengthening his expertise in global pharma markets.

“Nilesh joins us at a pivotal time in Firebrick’s development, as we seek to drive Nasodine approvals and licensing agreements in new markets across Asia-Pacific and elsewhere,” said Dr Peter Molloy, Executive Chairman, Firebrick Pharma. “Our stated goal is to go from two products in just three countries to four products in up to 10 countries over the next three years; Nilesh will be key to achieving that goal.” 

In addition, Wadhwa played a significant role in driving international business growth and strategic initiatives at Alembic Pharmaceuticals. His experience spans pharmaceuticals, medical devices, and consumer healthcare, with a strong track record of executing complex cross-border partnerships across Asia-Pacific, the United States, and Europe. Firebrick believes this appointment will strengthen its capabilities in global business development and licensing as it continues to expand its presence and partnerships in the pharmaceutical sector.